70 related articles for article (PubMed ID: 33619600)
1. Early Structural, Biochemical, and Metabolic Responses to Anlotinib in Patients With Progressive Radioactive Iodine Refractory Differentiated Thyroid Cancer.
Sun D; Zhang X; Sun Y; Mu Z; Wang H; Zhang Y; Liang J; Lin Y
Endocr Pract; 2024 May; 30(5):456-464. PubMed ID: 38447630
[TBL] [Abstract][Full Text] [Related]
2. The detection of SAS1B in serum provides clues for early diagnosis of thyroid cancer.
Yang HX; Yang Y; Li XD; Miao XM; Yang C; Zhi DF; Su H; Yang G; Gao J; Du CG; Li HJ; Song YL; Cao GF
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1410-1424. PubMed ID: 33629311
[TBL] [Abstract][Full Text] [Related]
3. BRAFV600E mutation is associated with increased prevalence of contralateral lymph-node metastases in low and low-to-intermediate risk papillary thyroid cancer.
Campennì A; Ruggeri RM; Giuffrè G; Siracusa M; Alibrandi A; Cardile D; La Torre F; Lanzafame H; Giacoppo G; Ieni A; Trimarchi F; Tuccari G; Baldari S
Nucl Med Commun; 2021 Jun; 42(6):611-618. PubMed ID: 33625185
[TBL] [Abstract][Full Text] [Related]
4. Risk Factors and Prediction Model for Lateral Lymph Node Metastasis of Papillary Thyroid Carcinoma in Children and Adolescents.
Liang W; Sheng L; Zhou L; Ding C; Yao Z; Gao C; Zeng Q; Chen B
Cancer Manag Res; 2021; 13():1551-1558. PubMed ID: 33623434
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a three-immune-related gene signature prognostic risk model in papillary thyroid carcinoma.
Gan X; Guo M; Chen Z; Li Y; Shen F; Feng J; Cai W; Xu B
J Endocrinol Invest; 2021 Oct; 44(10):2153-2163. PubMed ID: 33620716
[TBL] [Abstract][Full Text] [Related]
6. Percutaneous thermal ablation of lung metastases from thyroid carcinomas. A retrospective multicenter study of 107 nodules. On behalf of the TUTHYREF network.
Bonichon F; de Baere T; Berdelou A; Leboulleux S; Giraudet AL; Cuinet M; Drui D; Liberge R; Kelly A; Tenenbaum F; Legmann P; Do Cao C; Leenhardt L; Toubeau M; Godbert Y; Palussière J
Endocrine; 2021 Jun; 72(3):798-808. PubMed ID: 33770383
[TBL] [Abstract][Full Text] [Related]
7. Redifferentiation-facilitated radioiodine therapy in thyroid cancer.
Lamartina L; Anizan N; Dupuy C; Leboulleux S; Schlumberger M
Endocr Relat Cancer; 2021 Sep; 28(10):T179-T191. PubMed ID: 33690158
[TBL] [Abstract][Full Text] [Related]
8. Recurrence-Free Survival Analysis in Locally Advanced Pheochromocytoma: First Appraisal.
Moog S; Castinetti F; DoCao C; Amar L; Hadoux J; Lussey-Lepoutre C; Borson-Chazot F; Vezzosi D; Drui D; Laboureau S; Raffin Sanson ML; Lamartina L; Pierre P; Batisse Ligner M; Hescot S; Al Ghuzlan A; Renaudin K; Libé R; Laroche S; Deniziaut G; Gimenez-Roqueplo AP; Jannin A; Leboulleux S; Guerin C; Faron M; Baudin E
J Clin Endocrinol Metab; 2021 Aug; 106(9):2726-2737. PubMed ID: 33782697
[TBL] [Abstract][Full Text] [Related]
9. A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide.
Petrylak DP; Vaishampayan UN; Patel KR; Higano CS; Albany C; Dawson NA; Mehlhaff BA; Quinn DI; Nordquist LT; Wagner VJ; Siegel J; Trandafir L; Sartor O
ESMO Open; 2021 Apr; 6(2):100082. PubMed ID: 33744812
[TBL] [Abstract][Full Text] [Related]
10. Seizures and Neuropsychiatric Toxicity in Patients with Non-Metastatic CRPC Treated with New Antiandrogens: Systematic Review and Meta-Analysis.
Sopeña Sutil R; Silva Ruiz J; Garcia Gomez B; Romero-Otero J; Garcia-Gonzalez L; Duarte Ojeda JM; de Velasco G; Castellano Gauna D; Rodriguez Antolin A
Oncol Res Treat; 2021; 44(4):154-163. PubMed ID: 33735902
[TBL] [Abstract][Full Text] [Related]
11. 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer.
Bible KC; Kebebew E; Brierley J; Brito JP; Cabanillas ME; Clark TJ; Di Cristofano A; Foote R; Giordano T; Kasperbauer J; Newbold K; Nikiforov YE; Randolph G; Rosenthal MS; Sawka AM; Shah M; Shaha A; Smallridge R; Wong-Clark CK
Thyroid; 2021 Mar; 31(3):337-386. PubMed ID: 33728999
[No Abstract] [Full Text] [Related]
12. Darolutamide in hormone-sensitive and castration-resistant prostate cancer.
Palmieri VE; Roviello G; D'Angelo A; Casadei C; De Giorgi U; Giorgione R
Expert Rev Clin Pharmacol; 2021 May; 14(5):535-544. PubMed ID: 33685318
[No Abstract] [Full Text] [Related]
13. Alpha-Emitting Radionuclides: Current Status and Future Perspectives.
Miederer M; Benešová-Schäfer M; Mamat C; Kästner D; Pretze M; Michler E; Brogsitter C; Kotzerke J; Kopka K; Scheinberg DA; McDevitt MR
Pharmaceuticals (Basel); 2024 Jan; 17(1):. PubMed ID: 38256909
[TBL] [Abstract][Full Text] [Related]
14. Recurrent Extraneural Metastatic Medulloblastoma in an Adult Presenting With a Superscan and Treated With Radium-223.
Mou B; Cruz-Lim EM
Cureus; 2023 Feb; 15(2):e34732. PubMed ID: 36909024
[TBL] [Abstract][Full Text] [Related]
15. Advances in Functional Imaging of Differentiated Thyroid Cancer.
Klain M; Zampella E; Nappi C; Nicolai E; Ambrosio R; Califaretti E; Lamartina L; Schlumberger M; Deandreis D; Salvatore D; Cuocolo A
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638232
[TBL] [Abstract][Full Text] [Related]
16. RADTHYR: an open-label, single-arm, prospective multicenter phase II trial of Radium-223 for the treatment of bone metastases from radioactive iodine refractory differentiated thyroid cancer.
Deandreis D; Maillard A; Zerdoud S; Bournaud C; Vija L; Sajous C; Terroir M; Leenhardt L; Schlumberger M; Borget I; Leboulleux S
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3238-3249. PubMed ID: 33619600
[TBL] [Abstract][Full Text] [Related]
17.
Parihar AS; Mittal BR; Kumar R; Shukla J; Bhattacharya A
Thyroid; 2020 Apr; 30(4):557-567. PubMed ID: 31870227
[No Abstract] [Full Text] [Related]
18. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
Qiu ZL; Xue YL; Song HJ; Luo QY
Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
